Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Impact of Pentoxifylline Administration on the Modulation of Hyporesponsiveness to Erythropoietin Stimulating Agents in Hemodialysis Patients

Trial Profile

Impact of Pentoxifylline Administration on the Modulation of Hyporesponsiveness to Erythropoietin Stimulating Agents in Hemodialysis Patients

Status: Not yet recruiting
Phase of Trial: Phase 0

Latest Information Update: 17 Sep 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pentoxifylline (Primary)
  • Indications Anaemia
  • Focus Adverse reactions; Therapeutic Use

Most Recent Events

  • 24 Sep 2019 Planned End Date changed from 1 Sep 2019 to 1 Apr 2020.
  • 23 Sep 2019 Planned primary completion date changed from 1 Jul 2019 to 1 Apr 2020.
  • 23 Sep 2019 Planned initiation date changed from 1 Mar 2019 to 1 Oct 2019.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top